Thank you, Mr. Chairman.
Thank you to the witnesses.
I'm going to throw out a few questions. Then, if you could hold your powder dry, whoever wants to can jump in.
It's been a while since I looked at this issue, so I feel a bit dated, especially when you talk about a national angel organization, because my impression then was that in the continuum of finance, angel capital was friends and relatives, and that moved then to venture capital, which was slightly different. That has evolved, obviously, when you have a bunch of friends and relatives gathering into a national organization, so maybe you could help me to better understand the difference between angel capital and venture capital.
By the way, one of the issues I had with the labour-sponsored venture funds was that they wouldn't look at anything less than $500,000, so they started to group it together, and it seemed to lose some of its value over time.
We're looking at tax advantages. Surely making the scientific research tax credit refundable would help early-stage companies in loss carryforward positions in their early stages. Making that research credit refundable is something that's been around, and people have proposed it.
Also, I was glad the government extended the accelerated capital cost allowance, but surely they could have extended it for a period beyond one or two years if you look at the planning horizon of corporations.
When we looked at this some time ago, one of the problems.... Actually, this group I was with was looking at commercializing federal government research, because there is a fair bit of federal government research going on. We looked at commercializing it. One of the things we bumped into was intellectual property rights.
You know the problem of researchers: a lot of them aren't very good at tech transfer or tech diffusion, so intellectual property rights could maybe be an incentive. We looked at models. Mr. Simoneau, you mentioned the University of Waterloo. I was familiar with that one. Also, Guelph had a company called GUARD Inc. , which was the bridging corporation between the scientists and the capital markets. It seems to have worked very well; in fact I wondered, and we wondered, if we should actually do that at the federal level--have a bridging company between the scientists and the capital markets to help put the prototypes together and advance the file and get the capital to do that.
I'm wondering if you think we should be doing anything on intellectual property rights and if we should be doing anything with that particular model--building on the University of Waterloo model or the Guelph model--to provide that mechanism in between.